secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sharps Technology Inc. (STSS)
CIK:        0001737995
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001493152-23-033675
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sharps Tech signs $50M asset purchase agreement for InjectEZ facility and $400M+ supply deal with Nephron
--------------------------------------------------------------------------------

- Acquisition of InjectEZ syringe facility for $40.4M cash, $10M subordinated note, and warrants for 4% of fully diluted shares at $1.56.
- 10-year purchase agreement with Nephron for minimum $400M in copolymer syringes; initial $30M PO at closing, $45M+ per year from 2025.
- Signed term sheet for up to $75M debt financing from a middle-market lender to fund the acquisition and operations.
- Closing expected within 60 days, subject to customary conditions and securing committed financing; facility lease at $40,550/month.
- Deal transforms Sharps into commercial manufacturer with copolymer prefillable syringe capacity, targeting Q1 2024 deliveries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737995/000149315223033675/0001493152-23-033675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737995/000149315223033675/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer